Biogen Inc. (NASDAQ:BIIB) Morgan Stanley’s 22nd Annual Global Healthcare Conference September 4, 2022 10:00 AM ET Company Participants Mike McDonnell – Chief Financial Officer Priya Singhal – Executive Vice President and Head-Development Conference Call Participants Terence Flynn – Morgan Stanley Terence Flynn Okay, great. I think we're going to get started, but thanks for joining us, everyone. I'm Terence Flynn, the U.S. biopharma analyst at Morgan Stanley. We're very pleased to be hosting Biogen today. Fr ...

Positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA; Biogen plans to submit for regulatory approval of this investigational dose regimenHigher dose nusinersen regimen showed statistically significant improvement compared to a prespecified matched sham control groupAmong key measures of clinical efficacy, higher dose regimen showed positive trends compared to the approved dosing regimen CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) ...

Biogen (BIIB) stock has declined 20.9% so far this year against an increase of 28.6% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart below.BIIB Stock Underperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchThe company’s stock performance has been below most large drugmakers’ performance. Biogen's revenues declined 3.3% in the first six months of 2024. Sales of Biogen’s key multiple sclerosis (“MS”) drugs like Tecfidera and Tys ...

vuk8691/iStock via Getty Images Investment Overview I last covered Biogen (NASDAQ:BIIB), the Cambridge, Massachusetts based pharmaceutical company, focused primarily on central nervous system diseases, for Seeking Alpha in April this year, shortly after the company announced its Q1 2024 earnings - revenues of $1.71bn, down 3% year-on-year, and non-GAAP earnings per share ("EPS") of $3.7, up 8% year-on-year - giving the stock a "Buy" Recommendation. Nearly four months on, and with Q2 earnings having been ...

Investing based on the segment's long-term prospects is likely to be very lucrative.I predict that a gold rush in longevity medicines is going to start in the next half-decade or so. That's right: Biotech and pharma companies are going to try developing drugs that can extend human lifespan. And eventually, they're going to succeed, at least somewhat.The early competitors are already getting down to work. Soon enough, there will surely be great opportunities for investment -- as well as a sea of opportunitie ...

These companies have approved Alzheimer's treatments that could generate billions in revenue for their respective businesses.One thing that can help with the treatment of any disease is early detection, and Alzheimer's is no exception to that. And the good news is that in the near future, detecting cases of Alzheimer's disease could simply involve a blood test.A new wave of blood tests involves checking for p-tau217, which is an abnormal protein that can help accurately detect 90% of Alzheimer's cases. The ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores.What a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 0-19311 BIOGEN INC. (Exact name of registrant as specified in its charter) Delaware 33-0112644 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Iden ...

Biogen (BIIB) reported second-quarter 2024 adjusted earnings per share (EPS) of $5.28, beating the Zacks Consensus Estimate of $4.00. Earnings rose 31% year over year. Earnings benefited from the sale of one of Biogen's two priority review vouchers (PRV). Excluding PRV sales, adjusted earnings rose 18% in the quarter.Total revenues came in at $2.47 billion, flat on a reported basis and up 1% on a constant-currency basis from the year-ago quarter as lower sales of key multiple sclerosis (MS) drugs like Tecfi ...

Biogen Inc. (NASDAQ:BIIB) Q2 2024 Earnings Call Transcript August 1, 2024 8:30 AM ET Company Participants Chuck Triano - Head of IR Chris Viehbacher - President and CEO Alisha Alaimo - Head and President of North America Priya Singhal - Head of Development Travis Murdoch - Head of HI-Bio Mike McDonnell - CFO Conference Call Participants Salveen Richter - Goldman Sachs Evan Seigerman - BMO Capital Markets Michael DiFiore - Evercore ISI Nicole Gabreski - Piper Sandler Paul Matteis - Stifel Michael Yee - Jeffe ...